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Abstract Primary antibody deficiencies (PADs) are the most
common immunodeficiency in humans, characterized by low
levels of immunoglobulins and inadequate antibody responses
upon immunization. These PADs may result from an early
block in B cell development with a complete absence of pe-
ripheral B cells and lack of immunoglobulins. In the presence
of circulating B cells, some PADs are genetically caused by a
class switch recombination (CSR) defect, but in the most com-
mon PAD, common variable immunodeficiency (CVID), very
few gene defects have as yet been characterized despite vari-
ous phenotypic classifications. Using a functional read-out,
we previously identified a functional subgroup of CVID
patients with plasmablasts (PBs) producing IgM only. We
have now further characterized such CVID patients by a direct
functional comparison with patients having genetically well-
characterized CSR defects in CD40L, activation-induced cy-
tidine deaminase (AID) and uracil N-glycosylase activity
(UNG). The CSR-like CVID patients showed a failure in B
cell activation patterns similar to the classical AID/UNG de-
fects in three out of five CVID patients and distinct more
individual defects in the two other CVID cases when tested
for cellular activation and PB differentiation. Thus, functional
categorization of B cell activation and differentiation path-
ways extends the expected variation in CVID to CSR-like
defects of as yet unknown genetic etiology.
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Introduction
Primary immunodeficiencies (PIDs) are well recognized in the
Western world [1–3]. About 65 % of these PIDs show an
altered antibody production, categorized as primary antibody
deficiency (PAD). PADs can be caused by either a combined T
and B cell defect or a B cell-intrinsic defect. Among B cell-
intrinsic defects, at least five distinct groups are being recog-
nized, namely defects in the B cell development, migration,
activation, class switch recombination (CSR), and survival.
Despite this classification, many of the PADs remain without
a clear etiology [4].
The most prevalent of the PAD diagnoses is common var-
iable immunodeficiency (CVID), an antibody deficiency
caused by B cell dysfunction. The etiology of CVID seems
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to have a complex genetic cause, although few monogenetic
causesmay explain a CVID-like phenotype (e.g., TACI, ICOS,
CD19, CD20, and BAFFR) [4, 5].
Twenty-fold less common than CVID are the so-called hy-
per-IgM syndromes (HIGM) or class switch recombination
(CSR) defects, which are characterized by a low-to-normal
or elevated serum IgM in the absence of any other immuno-
globulin (Ig) isotypes in the serum. A number of unique gene
defects (e.g., in CD40L, CD40, AICDA, UNG, and IKBKG)
have been identified that lead to a defect in the CSR mecha-
nism required for the transition of the initial low-affinity IgM
to an Ig isotype of increased affinity [6, 7].
Defects in CD40L (TNFSR5 or CD154) encoded by the X-
linked CD40L gene represented the first reported CSR defect.
Identical abnormalities, both clinically as well as immunolog-
ically, have more recently been identified in the autosomal-
recessive syndrome of mutations in the gene for its counter-
receptor CD40 on B cells. In both syndromes, the lack of
functional expression of the surface molecule, leads to the
failure of a proper B cell-T cell signaling contact at the inter-
phase of germinal centers where a subset of primary activated
lymphocytes, i.e., the T follicular helper cells (Tfh) and naïve
B cells meet in the lymph nodes, mucosal lymphoid tissues, or
marginal zones of white pulp in the spleen [8]. After success-
ful interaction between antigen-specific Tfh cells and B cells,
the B cells start to proliferate and initiate a cell-intrinsic pro-
cess of Ig affinity maturation by class switch and
hypermutation, in which B cell-specific enzymes such as
activation-induced cytidine deaminase or AID (encoded by
AICDA) and uracil N-glycosylase activity (encoded by
UNG) are involved [9–11].
Within the diagnosis and definitions of CVID, there are
many overlapping features with CSR-defects. This is also
recognized in the list of clinical criteria provided by the
European Society for Immunodeficiencies (ESID). In
CVID, the initial steps of B cell development in the bone
marrow are supposed to have normally proceeded. In
most patients, there are mature B cells circulating but
in vivo antibody production fails. Many studies have tried
to classify these unidentified defects in different subtypes
of CVID using phenotyping and a description of the B
cell recombination history [12–17].
We have previously used a comprehensive culture sys-
tem to characterize CVID in functional terms by the ca-
pacity of the patient’s B cells to proliferate and differen-
tiate into Ig-secreting plasmablasts (PBs) [15]. In this
way, we have identified a subgroup of CVID patients,
which was highly reminiscent of CSR-like B cell defects.
Since this subgroup of CVID patients has not been well
described, we have further characterized their B cell func-
tions in greater detail as a separate group and compared
the results of these CVID patients to those of patients with
genetically well-defined CSR-defects.
Materials and Methods
Samples This study was approved by the Medical Ethics
Committee of the Academic Medical Center (Medisch
Ethische Toetsingscommissie AMC) in Amsterdam, and was
performed in accordance with the Declaration of Helsinki.
Heparinized peripheral blood samples from patients suspected
or diagnosed with CVID were collected for routine diagnos-
tics. Cord blood samples from healthy term-newborn donors
were collected by nurses from the maternity ward with paren-
tal consent, all samples were collected anonymously for the
authors and none of the authors had access to clinical data,
samples were used in accordance with the Dutch law regard-
ing the use of discarded material for research purposes.
Healthy adult control samples (n = 20) were available from
buffy coats obtained from Sanquin blood bank Amsterdam,
all samples were acquired anonymously. None of the authors
had access to clinical data from any control samples. PBMCs
were isolated using standard density gradient centrifugation
techniques using Lymphoprep (Nycomed, Oslo, Norway)
and stored in liquid nitrogen until use. The CSR-deficient
patients were identified via clinical presentation and corre-
sponding diagnosis by gene analysis (of CD40L, CD40,
AID, or UNG) by classical Sanger sequencing, all CVID pa-
tients were negative for these defects.
Flow Cytometry PBMCs were resuspended in phosphate-
buffered saline (PBS), containing 0.5 % (w/v) BSA and
0.01 % sodium azide. PBMCs were incubated with saturating
concentrations of fluorescently labeled conjugated monoclo-
nal antibodies (MoAbs). Analysis of cells was performed
using a FACSCanto-II flowcytometer and FlowJo software.
The following directly conjugated MoAbs were used for flow
cytometry: CD19-PerCP-Cy 5.5, CD19 Alexa-700, CD20-
APC, CD20-PerCP-Cy 5.5, CD38 PE-Cy7, CD138 APC,
IgG-PE, IgD-PE, and IgA-PE from BD-biosciences (San
Jose, USA), CD27-FITC from Sanquin (Amsterdam, the
Netherlands), IgM-PE from ITK-diagnostics (Uithoorn, the
Netherlands).
BCell Activation In Vitro PBMCs were resuspended in PBS
at a concentration of 5–10 × 106 cells/ml and labeled with
0.5 μM carboxyfluorescein succinimidyl ester (CFSE)
(Molecular Probes) in PBS for 10 min at 37 °C under constant
agitation. Cells were washed and subsequently resuspended in
IMDM supplemented with 10 % fetal calf serum
(BioWhittaker), antibiotics, and 3.57 × 10–4 %(v/v) β-
mercapto-ethanol (Merck). Labeled PBMCs containing a
fixed number of B cells (1 × 105 per well) were cultured in
48-well flat-bottomed plates for 6 days at 37 °C and stimulat-
ed with saturating amounts of 5 μg/ml anti-IgM mAb (clone
MH15; Sanquin), 1:500 anti-CD40 mAb ascites (clone 14G7;
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Sanquin), 20 ng/ml IL-21 (Invitrogen), or 1 μg/ml CpG
oligodeoxynucleotide 2006 (Invivogen), with 100 U/ml IL-2
(R&D Systems). Proliferation of the B cells was assessed by
measuring CFSE dilution by flow cytometry.
IgG and IgM ELISA Supernatants were tested for secreted
IgM and IgG with an in-house ELISA using polyclonal rabbit
anti-human IgG and IgM reagents and a serum protein cali-
brator all from Dako (Heverlee, Belgium), as described before
[15]
Statistics Differences between immunoglobulin levels were
calculated by two-sided, two-tailed Student’s t test. For corre-
lations, the Spearman nonparametric correlation test was used.
P < 0.05 was considered statistically significant.
Results
Patient Selection
Using our previously described experimental conditions for B
cell activation [15], we have to date functionally screened over
40 PAD patients who were suspected or diagnosed with CVID
by their clinicians because of their clinical presentation, low
serum IgG and IgA, and a lack of humoral response to poly-
saccharides at presentation.
With this screening assay, we selected a small series of
patients who were considered CSR-like CVID cases because
of an increased IgM in their serum at diagnosis (more than
2SD above the cutoff for normal values measured at least two
times apart) and/or documented BIgM-only^ immunoglobulin
isotype production in vitro (Tables 1 and 2).
When categorized according to the Freiburg, Paris, and
EUROclass classification [17], these CSR-like CVID patients
fitted in the B+ CVID patient category with a variable number
of memory B cells but without a significant expansion of
transitional B cells (Table 3).
These selected CVID patients had normal T cell numbers
and function upon T cell activation toward anti-CD3, anti-
CD3/anti-CD28, IL7, or IL15, as indicated in proliferation
assays as described previously (data not shown).
Normal Peripheral Blood B Cell Phenotypes
Within the B cell compartment (CD20+CD19+), various B cell
subsets are routinely distinguished, i.e., transitional
(CD38highCD24high), naïve (sIgD+CD27−), non-switched
(sIgD+CD27+), and switched memory (sIgD−CD27+) B cells.
During childhood, the human B cell compartment changes
from a completely naive to a more differentiated phenotype
as a consequence of the expansion of CD27+ memory B cells.
Within the CD27+ memory B cell compartment, surface
immunoglobulin receptor expression can be used to further
distinguish sIgM+, sIgG+, and sIgA+ memory B cells
[18–20]. In the adult PBMC fractions, the B cell phenotype
demonstrates the presence of a clear memory B cell compart-
ment including sIgG+ and sIgA+ B cells, both of which are
absent in cord blood PBMCs where all B cells are naïve
(Fig. 1 and Supplementary Fig. Fig. 1).
Patients with Classical CSR Defects Show Phenotypic
Differences in Peripheral B Cells
Patients with genetically well-characterized CSR defects
were included (Table 2) for comparison with the five
CSR-like CVID patients mentioned earlier (Table 1).
Next to cord-blood samples and healthy adult samples,
we immunophenotyped the classical CSR cases to di-
rectly compare with the CSR-like CVID patients
(Table 3). As reported before [8], the circulating B cells
in patients with CD40L gene defects consisted of naïve
B cells only and no memory B cells. These patients did
have a slightly increased number of transitional B cells,
similar to cord blood samples. On the other hand, pa-
tients who suffered from defects in AICDA showed nor-
mal numbers of non-switched B cells and even some
memory sIgD−CD27+ B cells that had not undergone
any class switching, i.e., these cells did not show any
sIgG or sIgA expression and expressed sIgM only.
Similar to patients with an AICDA gene defect, the in-
dividual that had been identified with an UNG gene
defect [15], contained non-switched sIgM+ B cell popu-
lation in the absence of sIgD−CD27+ B cells, indicating
a lack of switched sIgG+ and sIgA+ memory B cells
(Table 3).
Plasmablast Formation Upon Activation of Healthy B
Cells
The capacity of the B cells to proliferate and differen-
tiate upon in vitro activation in a 6-day culture was
tested with CpG in the presence of a small B cell acti-
vating dose of IL-2 (to which purified T cells do not
show proliferation and cytokine induction and acts by
direct B cell activation of the IL-2 receptor) [15, 21]. T
cell-dependent B cell stimulation was mimicked by the
combination of antibodies against sIgM to trigger the B
cell antigen-receptor (BCR) on the majority of circulat-
ing B cells in the blood, together with costimulatory
CD40 activation and Tfh cell-associated IL-21
(αIgM/αCD40/IL-21) [22]. To check for the T cell
function and the indirect effects of T cell proliferation
on subsequent B cell activation, we also stimulated the
PBMCs with the combination of T cell-specific
αCD3/αCD28 MoAbs, in which the common-gamma
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(CD132)-cytokine receptors play an essential role as we
had previously described [18].
In control experiments, we showed that upon activa-
tion, the adult B cells proliferated and differentiated into
PBs (sIgD−CD27++CD38++) (Fig. 2 and Supplementary
Fig. Fig. 2). Cord blood B cells showed similar re-
sponses but largely failed to differentiate into PBs after
6 days of stimulation. Both adult and cord blood B cells
showed proliferation upon T cell-specific αCD3/αCD28
stimulation. The αCD3/αCD28 activation downregulated
sIgD only on adult and not the cord blood B cells after
6 days of culture, but PBs expressing high levels of
CD27 or CD38 did not develop under these conditions.
Plasmablast Formation Upon CSR-Defective B Cell
Activation
We subsequently analyzed the B cells of the known
CSR defect patients. With regard to CD40L-deficient
B cells, these cells proliferated normally upon CpG/IL-
2 stimulation but B cells could hardly differentiate into
CD27++CD38++ PBs. Stimulation with αIgM/αCD40/IL-
21 induced vigorous B cell proliferation without any
differentiation into PBs at all (Tables 4 and 5).
Remarkably, the αCD3/αCD28-mediated T cell activa-
tion failed completely to induce any B cell proliferation
in both CD40L-deficient patients. Identical responses
were found in a CD40-deficient patient, demonstrating
the importance of CD40L-CD40 interactions (data not
shown).
Stimulation of the B cells of AICDA-mutated patients
resulted in a different B cell signature in our B cell
cultures. Both B cell proliferation and differentiation
into PBs were observed upon activation with CpG/IL-
2. In contrast, αIgM/αCD40/IL-21 stimulation induced
B cell proliferation but no PB formation—similar to
cord blood B cells and the CD40L- or CD40-deficient
B cell cultures. With αCD3/αCD28 stimulation, AID-
deficient B cells proliferated normally, but did not
downregulate sIgD (in contrast to control adult B cells).
The reactivity of B cells of the UNG-mutated patient
was an almost complete functional phenocopy of the
Table 1 Clinical characteristics for CSR-like CVID patients at presentation
Patient #1 #2 #3 #4 #5
Year of birth 1989 1939 1958 1965 1944
Gender Male Male Male Female Female
Age at diagnosis 18 20 14 41 60
Clinical presentation
Appendicitis Rec. lung infections Bronchiectasis Bronchiectasis Rec. lung infections
Rec. fever Tonsillitis Deafness ITP Bronchiectasis
Pneumonia Mild mental retardation Splenomegaly
Sinusitis Dental caries
Gene analysis
CD40L neg neg neg neg neg
CD40 neg neg neg neg neg
UNG neg neg neg neg neg
AICDA neg neg neg neg neg
PI3Kdelta neg neg neg neg neg
Immunoglobulins at presentation (g/L)
IgG <0.3 <0.1 1.2 2.5 <0.3
IgM <0.03 0.46 7.05 5.27 2.5
IgA <0.04 <0.05 <0.22 <0.22 <0.04
IgE <2 ND <2 <2 ND
B cell subsets at presentation
IgD+CD27− (naive) 80.1 55.4 74 92 95.9
IgD+CD27+ (non-switched memory) 12.2 42.8 18.6 5 1.3
IgD−CD27+ (switched-memory) 4.2 1 0 0.7 0.2
IgD−CD27− (double negative) 3.5 0.8 7.4 2.3 2.6
Year of birth, patient gender, age at diagnosis, clinical presentation, mutations (neg tested negative), immunoglobulin levels at presentation, and B cell
subset at presentation is shown
ND not done, HUS Hemolytic-uremic syndrome, ITP Idiopathic thrombocytopenic purpura
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AICDA-mutated patients. B cells from the UNG-mutated
patient showed less proliferation when stimulated with
αIgM/αCD40/IL-21, and showed no differentiation into
PBs.
Thus, B cells from patients with CD40L or CD40 CSR
defects showed an in vitro pattern of proliferation and differ-
entiation responses different from AID or UNG-defective B
cells (Tables 4 and 5).
Table 2 Clinical characteristics for known CSR patients at presentation
Patient CD40L #1 CD40L #2 AID #1 AID #2 UNG
Year of birth 1985 1980 1975 1972 1994
Gender Male Male Female Male Male
Age at diagnosis 3 2 20 6 3
Clinical presentation
Bronchiectasis Rec. neutropenia Vasculitis Rec. lung infections Rec. lung infections
Sinusitis HUS Rec. breast abces Bronchiectasis Rec. Otitis
Cold sores Meningococcal meningitis Failure to thrive
Urticaria Cutaneous lupus
Gene analysis
CD40L c.464T>C,
(p. Leu155Pro)
c.435delC – – –
UNG – – – – c.630_632delCCT
AICDA – – c.156+1T>G c.317T>C (p. L106P) –
Immunoglobulins at
presentation (g/L)
IgG 1.5 <0.1 <0.1 <0.1 <0.1
IgM 7.5 3.5 9.0 ND 0.5
IgA <0.22 <0.1 <0.1 ND <0.1
IgE <2 ND ND ND ND
B cell subsets at presentation
IgD+CD27− (naive) 92 ND ND ND 68.6
IgD+CD27+ (non-switched memory) 7 ND ND ND 27.4
IgD−CD27+ (switched-memory) 0 ND ND ND 2.4
IgD−CD27− (double negative) 1 ND ND ND 1.6
Table 3 B cell subset
characteristics at time of analysis
for CSR patients and CSR-like
CVID patients
B cell subsets
Identifier %Naive %Non-Switched %Memory %IgD−CD27− %Transitional
Adult control (45–85) (5–25) (9.0–35) (1.3–4.3) (1.7–3.7)
Cord blood (97–100) (0.0–1.6) (0.0–0.2) (0.1–1.2) (5.0–12.0)
CD40L 94.3 4.0 0.6 0.9 7.7
AID 71.9 19.6 5.1 3.2 4.6
UNG 83.8 13.0 0.4 2.6 1.56
Patient #1 80.1 12.2 4.2 3.5 1.2
Patient #2 54.9 42.5 0.9 1.5 0.1
Patient #3 70.3 21.9 5.6 2.2 1.6
Patient #4 92.6 1.9 0.9 4.6 2.3
Patient #5 92.5 4.5 1.4 1.6 3.2
The range for all different peripheral B cell subsets of adult control (N = 25) and cord blood (N = 15) samples, with
average percentages (mean) of the different B cell subsets for the CSR patients and CSR-like CVID patients (from
N = 3–5 experiments), gated for CD19+ cells is shown
ND not done
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In Vitro Release of Immunoglobulins in Case of Known
CSR Defects
Both IgG and IgMwere measured in the supernatants of the 6-
day cultures (Fig. 3). Stimulation with CpG/IL-2 resulted in
the production of IgG and IgM by adult B cells, but only IgM
was produced by cord blood B cells.
Since stimulation of the cell cultures with αIgM/αCD40/
IL-21 makes the detection of IgM unreliable because of the
addition ofαIgM, we changed to stimulation with αCD40/IL-
21 alone, resulting in similar B cell proliferation and PB dif-
ferentiation in adult control cells (data not shown). Both
αIgM/αCD40/IL-21 and αCD40/IL-21 stimulation resulted
in the release of IgG in control PBMC cultures but—as ex-
pected—not in cord blood-derived samples. Noticeably, we
did not detect any IgM release withαCD40/IL-21 stimulation.
Although strong proliferation was induced upon
αCD3/αCD28 stimulation, neither adult nor cord blood B
cells produced IgG or IgM under these conditions.
As expected, none of the B cell cultures performed with
PBMCs from CSR-deficient patients produced any IgG
in vitro for all the conditions tested. In contrast, CpG/IL-2
stimulation resulted in massive IgM release in 6-day cultures
by the cells from patients with mutations in UNG or AICDA,
and to a lesser extent by those with the CD40L mutations
(Table 4). B cells of patients with an AICDA defect were
unique in their capacity to produce IgM when stimulated with
αCD40/IL-21, in contrast to B cells from other genetically
characterized CSR defects or from any of the normal controls
tested thus far (over 100 individuals to date).
Diagnostic Categorization of Unidentified CSR-like CVID
The patients had normal or increased serum IgM in vivo, apart
from patient #1, who had no detectable IgM in serum. All
patients had circulating B cells that produced relatively large
amounts of IgM without any IgG and IgA upon in vitro
activation.
Their B cell functionality was compared to the B cell cul-
tures of our patients with known CSR defects (Fig. 3, Tables 4
and 5). One of the selected CSR-like CVID patients had a
child with exactly the same immunophenotype and clinical
Fig. 1 Representative figures of the phenotype of circulating B cells
from healthy adult controls, healthy cord bloods, and CD40L-, AID-,
and UNG-deficient patients. B cell subsets of representative blood
samples from healthy adult and cord blood samples, as well as from
genotyped CD40L-, AID-, and UNG-deficient patients. Numbers
indicate mean percentages of multiple experiments in the corresponding
quadrant. Healthy adult controls (N = 20), healthy cord bloods (N = 15),
and CD40L-, AID-, and UNG-deficient patients (N = 2–5)
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diagnostic features (patient #2). In all of these patients, classi-
cal CSR defects were excluded, i.e., phenotypic or genetic
defects in CD40L, CD40, AICDA, UNG, or the recently iden-
tified PI3K defects, established in Activated PI3K-p110delta
syndrome, types 1 and 2 (APDS-1 and APDS-2, caused by a
number of gain-of-function mutations in PIK3CD and
PIK3R1, respectively) [23–25].
The immunophenotype of the peripheral circulating B cells
of these CVID patients was compared to the B cell phenotype
of the patients with classical CSR defects (Fig. 4). Three of our
patients (patients #1, #2, and #3) looked very similar to those
with an AICDA or UNG defect, i.e., their B cell compartment
comprised of naïve and non-switched B cells only, with very
few if any switched memory B cells. The other two patients
(patients #4 and #5) resembled the CD40L-deficient patients,
i.e., completely naïve in their B cell compartment without any
circulating non-switched and switched CD27+ memory B
cells.
Also, after stimulation with CpG/IL-2 and αCD40/IL-
21 (Table 4 and 5), our results showed that patients #1,
#2, and #3 mostly resembled the B cell-intrinsic AID/
UNG-deficient patients, i.e., the B cells proliferated un-
der all conditions of B cell activation tested and in-
duced proper B cell differentiation and IgM production
in vitro upon CpG/IL-2 activation.
On the other hand, patients #4 and #5 behaved dif-
ferently. Patient #4 again resembled the CD40L-
deficient patients with a normal proliferation upon
CpG/IL-2 stimulation and αIgM/αCD40/IL-21 but with-
out any PB differentiation. However, this patient’s B
cells demonstrated a completely normal B cell prolifer-
ation upon T cell activation with αCD3/αCD28 which
was absent with CD40L- or CD40-deficient B cells
(Fig. 2 and data not shown).
In contrast to the other CSR-like cases as well as the
classical CSR patients, the B cells of patient #5, who
presented with an elevated serum IgM upon diagnosis,
repeatedly showed a lack of proliferation upon any kind
of B cell stimulation and failed to differentiate to PBs
with almost no IgM production (6–10 % of control
Fig. 2 Proliferation and differentiation of B cells from CSR-deficient
patients upon activation. The capacity of B cells from healthy adult
controls, healthy cord bloods, and CD40L-, AID-, and UNG-deficient
CSR patients to proliferate and differentiate in vitro were tested. CFSE-
labeled PBMCs were cultured for 6 days, normalized for B cell numbers
(1 × 105 B cells/well). Tcell-independent B cell activationwas tested with
CpG in the presence of IL-2. T cell-dependent B cell stimulation was
mimicked by the combinations of αIgM/αCD40/IL-21. Effect of T cell
stimulation was mimicked by αCD3/αCD28 stimulation, targeting T
cells specifically. Representative FACS plots are shown of B cell subset
distribution after 6 days of culture in the presence of the indicated stimuli.
Gated on CD19+ lymphocytes to show CFSE dilution indicating
proliferation after 6 days of culture, and to demonstrate the emergence
of the subsets of Ig-producing B cells, i.e., plasmablasts and/or
plasmacells (sIgD−/CD27++/CD38++)
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values) and IgG (or IgA) production, hence not resem-
bling any of the tested CSR patients.
Discussion and Conclusions
We describe a subgroup of patients with CVID identified by a
distinct failure of in vitro activation of the B cells into IgG/
IgA-secreting PBs in the presence of a normal or increased
IgM secretion. This defect in Ig class switching is not based on
known CSR gene defects. Clinically, these patients were
mainly characterized by recurrent infections.
When combining our previously described functional B
cell classification with the results of our cultures in a series
of patients who had been genetically characterized by one of
the currently known CSR defects, we can add an additional
layer to identify the possible B cell defects among patients
hitherto diagnosed with CVID.
Having determined the B cell reactivity of the most com-
mon CSR defects in our culture system by analysis of prolif-
eration, differentiation, and PB formation, we noticed a strik-
ing similarity between a subgroup of CVID patients and pa-
tients with genetically well-characterized CSR defects. In the
subgroup of CSR-like CVID patients, a major T cell defect
was excluded by the normal T cell counts and subsets (naïve,
memory, memory-effector Tcell subsets according to standard
CD45RA/CD27 staining [26]) (Supplementary table 1), as
well as their proliferative capacity upon various stimuli in-
cluding αCD3 and αCD3/αCD28 stimulation (data not
shown).
The functional data from the CSR-like CVID patients
reported here suggest that the failure of B cells to pro-
liferate and differentiate upon stimulation may be local-
ized at distinct stages of differentiation. One patient
identified in this small series of CVID cases best fitted
the category of a very early B cell activation defect
(patient #5), because both B cell proliferation and dif-
ferentiation were clearly defective.
The signal to recombine to a particular switch region
comes from the cell surface. Cytokines such as
interleukin-21 or IL-4, and appropriate co-stimulation
with CD40L induce the production of so-called sterile
transcripts from promoters that are upstream of the
targeted switch regions. A recent study has highlighted
the mechanism of how such transcription through the
immunoglobulin switch region produces a non-coding
RNA that guides the enzyme AID to DNA in a
sequence-specific manner to promote antibody CSR
[27].
As had been shown before [28], in vitro stimulation
of B cells that lacked AID resulted in the production of
sterile transcripts without CSR. While this recent study
from Zheng et al. [27] also suggest that the switch RNA
debranching enzyme DBR1 influences CSR, the relative
difficulty of performing these experiments in these pa-
tient materials did not permit us to further investigate at
which steps these CSR-defective CVID patients fail in
Table 4 Proliferation, plasmablast differentiation and release of
immunoglobulin after 6-day stimulation with CpG/IL-2 of CSR patients
and CSR-like CVID patients
CpG/IL-2
Identifier Proliferation CD27++ CD38++ CD20dull IgG IgM
Adult
control
+ + + + + +
Cord blood + +/− +/− +/− − ++
CD40L + +/− +/− − − +/−
AID + + + + − ++
UNG + +/− + − − +
Patient #1 + + + + − ++
Patient #2 + +/− + − − +
Patient #3 + + + + − +/−
Patient #4 + +/− +/− − − +/−
Patient #5 +/− − − − − +/−
Proliferation (measured by CFSE dilution), differentiation into
plasmablast (phenotypical markers (CD27++ , CD38++ , and CD20dull ))
and release of immunoglobulin into the supernatant (by ELISA) after
stimulation with CpG/IL-2 are scored in comparison with healthy adult
controls: ++ (above controls), + (average), +/− (below controls) or –
(absent). All data shown are gated on the CD19+ B cell population.
Adult control (N = 25), cord blood (N = 15), CSR patients and CSR-like
CVID patients (N = 3–5)
Table 5 Proliferation, plasmablast differentiation and release of
immunoglobulin after 6-day stimulation with aCD40/IL-21 of CSR
patients and CSR-like CVID patients
aCD40/IL-21
Identifier Proliferation CD27++ CD38++ CD20dull IgG IgM
Adult
control
+ + + + + −
Cord blood + +/− +/− +/− − −
CD40L + − − − − −
AID + − − − − +/−
UNG + − − − − −
Patient #1 + − − − − +/−
Patient #2 +/− − − − − −
Patient #3 + − − − − ND
Patient #4 + − − − − −
Patient #5 +/− − − − − −
Proliferation (measured by CFSE dilution), differentiation into
plasmablast (phenotypical markers (CD27++ , CD38++ and CD20dull ))
and release of immunoglobulin into the supernatant (by ELISA) after
stimulation with aCD40/IL-21 are scored in comparison with healthy
adult controls: ++ (above controls), + (average), +/− (below controls) or
– (absent). All data shown are gated on the CD19+ B cell population.
Adult control (N = 25), cord blood (N = 15), CSR patients and CSR-like
CVID patients (N = 3–5)
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the CSR process. Noticeably, the B cell cultures of our
patients reacted differently to stimulation, suggesting
that the CSR failure was not identical. It would be
interesting to investigate whether sterile transcripts,
Fig. 4 Representative diagrams
of the circulating B cell
phenotype at time of analysis. B
cell subsets of representative
blood samples from a healthy
adult control, healthy cord blood,
CD40L-, AID-, UNG-deficient
CSR patients and five CSR-like
CVID patients. Numbers indicate
mean percentages of multiple
experiments in the corresponding
quadrant. Healthy adult controls
(N = 20), healthy cord bloods
(N = 15), CD40L-, AID- and
UNG-deficient patients (N = 2–5),
CSR-like CVID patients (N = 2–5)
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Fig. 3 Production and release of immunoglobulins from CSR-deficient
patients and CSR-like CVID patients uponB cell activation. IgM and IgG
levels were measured in the supernatants by ELISA after 6 days of
culture. Plotting multiple experiments per patient group (N = 2–5).
Immunoglobulin production shown is normalized to that of the healthy
control samples used in each separate experiment, production of Ig’s after
stimulated with CpG/IL-2 is set at 100 %. Controls range from 2700 to
5000 pg/ml for IgG and 4000–9000 pg/ml for IgM. ND not done
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SHM, or AICDA expression are normal in these patient
B cells or whether signaling or metabolic processes oth-
erwise determine their failure in CSR activity.
In functional terms, the CD40L-deficient patients and pa-
tient #4 were most similar apart from the defective B cell
proliferation after αCD3/αCD28-mediated T cell activation
when CD40L is deficient. We have observed a similar lack
of αCD3/αCD28-mediated B cell response in leaky X-CID
patients with hypomorphic IL2RG gene mutations encoding
the common gamma chain [18, 29]. We therefore conclude
that CD40L-CD40 interaction together with the cytokine pro-
duction by Tcells—and in particular, IL-21 as suggested from
blocking experiments (data not shown)—are responsible for
the B cell proliferation by αCD3/αCD28-mediated T cell ac-
tivation [8, 30]. Patient #4 can be clearly distinguished from
these activation defects.
Finally, the B cells of CSR-like patients #1, #2, and #3
showed clear overlap with the B cell-intrinsic CSR defects
of AID- and UNG-deficient patients, where normal B cell
proliferation and differentiation into PBs was found, as well
as massive in vitro production of IgMwithout any IgG or IgA.
Absence of sIgG and sIgA on the B cells ex vivo supports the
lack of Ig-isotype switched memory cells. The lack of IgG/A
production with normal in vitro proliferation and differentia-
tion defects resembles the cord blood phenotype; however,
cord blood samples have a completely naïve B cell subset
whereas AID- and UNG-deficient patients have clear popula-
tion of circulating sIgD+CD27+ B cells. Another interesting
finding is that patient #1 as well as our AID-deficient patients
produce a moderate amount of IgM when stimulated with
αC40/IL-21, this in contrast to all other samples. Potentially
showing the failure in class switching, or a compensatory
mechanism for the lack of IgG production.
Our approach to categorize CVID-patients according to
functional B cell activation and differentiation may give addi-
tional information about the underlying signaling pathways
contributing to the observed B cell defects in CVID.
Although a single gene defect may still underlie this dis-
tinct CSR-like CVID subgroup, our data already demonstrate
variability in these CSR-like B cell defects, making a mono-
genetic cause rather unlikely. Even within the same PID sub-
category, defects can lead to variable phenotypes, which could
be the result of genotype (hypomorphic mutations), the micro-
bial exposure, and/or the complex nature of the gene defect
causing a disbalance or loss of strength of multiple activating
signals. For instance, data from the recently described defects
in the mTOR-AKT-PI3K pathway in humans and mice al-
ready hints to such variability in the outcome of functional B
cell development [31–34]. In APDS, the observed
dysglobulinemia may encompass a slight increase of IgM
and decrease in IgG or IgG-subclass levels. Also, mutations
in the CTLA4 gene have recently been shown to cause CVID
with highly variable and incomplete penetrance [35, 36].
For our subgroup of functionally characterized CSR-like
CVID patients, whole genome sequencing has been undertak-
en. Known PID genes according to the IUIS list of approved
PIDs [37] did not show any defect in the CSR-like CVID
cases to date. RNA expression arrays may for that reason be
informative to define this subgroup in more detail to further
explore whether a disbalance in B cell-activating signals or
additional genes involved in CSR, may be involved.
In sum, our culture system to functionally test CVID pa-
tients by determining the capacity of peripheral blood B cells
to proliferate and differentiate into activated Ig-secreting PBs
may be useful to characterize hitherto undescribed functional
PAD subgroups. Our data on a distinct CVID subgroup indi-
cates the presence of B cell defects comparable with known
CSR patients. Their recognition as a subgroup in functional
terms may help to identify the underlying defects in B cell
activation.
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